Described herein are methods of treating, diagnosing, and/or prognosing a disease in a subject relating to detection of the glycosylation state of the antibodies present in the subject. In some embodiments, the disease can be an infection. In some embodiments, an antibody glycosylation state that is indicative of the presence of a disease, or a need for treatment of a disease can be reduced glycosylation (e.g., galactosylation, sialation, fucosylation, and/or afucosylated branched glycoforms).

Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.

Provided are high affinity Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.

An antibody for the detection of an antigen associated with mycobacteria in an in vitro sample urine of a subject, wherein said antigen comprises Man LAM (Mannose capped Lipoarabinomannan), said antibody specifically binding to said Man LAM molecules from said urine, wherein said antibody binds to said Man LAM with an affinity having a KD of 310.sup.8 M or less, and wherein said antibody binds to LAM molecules that are not capped or that are capped with inositol phosphate with an affinity having a KD of 10 .sup.3 M or more; and an antibody for use of same.

A hybridoma cell strain secreting a nifursol residue marker monoclonal antibody prepared in the following way: BALB/c mice are subjected to the first immunization with a complete Freund's adjuvant, subjected to booster immunization with an incomplete Freund's adjuvant for four times, and subjected to rush immunization once with nifursol residue marker complete antigen without a Freund's adjuvant so that the BALB/c mice are immunized; the spleen cells of the immunized mice with high titer and low IC50 were fused with mouse myeloma cells by a PEG method, and the fused cells are screened through indirect competitive ELISA and subcloned three times. The monoclonal antibody secreted by this cell strain has good specificity and detection sensitivity (IC50 value of 2 g/L) to the nifursol residue marker and can be used for residue detection of the nifursol residual marker in food.

The present disclosure discloses a process for immobilizing polypeptides on a surface, said method comprising: (a) coating a surface with a molecule to capture biotin tagged polypeptide to obtain a coated surface; and (b) contacting at least two biotin tagged polypeptides with the coated surface of step (a) to obtain immobilized polypeptides, wherein the biotin tagged polypeptide comprises a biotin linked to a recombinant polypeptide. The present disclosure further discloses an in-vitro method for detecting at least one binder molecule in a sample, and a process for obtaining biotin tagged polypeptide.

A hybridoma cell strain secreting a nifursol residue marker monoclonal antibody prepared in the following way: BALB/c mice are subjected to the first immunization with a complete Freund's adjuvant, subjected to booster immunization with an incomplete Freund's adjuvant for four times, and subjected to rush immunization once with nifursol residue marker complete antigen without a Freund's adjuvant so that the BALB/c mice are immunized; the spleen cells of the immunized mice with high titer and low IC50 were fused with mouse myeloma cells by a PEG method, and the fused cells are screened through indirect competitive ELISA and subcloned three times. The monoclonal antibody secreted by this cell strain has good specificity and detection sensitivity (IC50 value of 2 g/L) to the nifursol residue marker and can be used for residue detection of the nifursol residual marker in food.

The present invention provides novel Mycobacterium avium subspecies paratuberculsis (MAP) derived antigens which may be used to diagnose and thereafter effectively treat animals that have been infected with MAP, Further provided are methods of determining whether an animal is infected with MAP, and methods of diagnosing and treating Johne's disease. The invention also relates to a kit for the implementation of the methods.

The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.